Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma

Emeline Colomba,Jérôme Alexandre,Gwénaël Le Teuff,Catherine Genestie, Dahna Coupez,Isabelle Ray Coquard,Pierre Emmanuel Brachet,Sixtine de Percin, Christophe Sajous,Michel Fabbro,Nicolas Delanoy,Florence Joly,Jean Sebastien Frenel,Patricia Pautier,Alexandra Leary

Gynecologic Oncology（2023）

引用 0|浏览16

暂无评分

摘要

•Approximately, 30% of primary endometrial cancers are MMRd/MSI-H.•In this population, PD-1 and PDL-1 inhibitors therapy have shown response rates between 40 and 60%.•However their response to 1st line platinum is unknown.•We report that the response rate is similar to an all-comer population but PFS is shorter than expected.

查看译文

关键词

Endometrial carcinoma,MMRd/MSI-H,Chemotherapy,DNA repair,MMR,Immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要